Gainers

• CytomX Therapeutics (NASDAQ:CTMX) shares increased by 56.2% to $7.31 during Monday's pre-market session. The market value of their outstanding shares is at $792.9 million. As per the news, the Q4 earnings report came out today.
• AquaBounty Techs (NASDAQ:AQB) shares rose 28.06% to $1.2. The market value of their outstanding shares is at $3.6 million.
• AirSculpt Technologies (NASDAQ:AIRS) shares moved upwards by 21.62% to $2.25. The market value of their outstanding shares is at $115.5 million.
• Lumexa Imaging Holdings (NASDAQ:LMRI) shares rose 18.12% to $14.4. The company's market cap stands at $1.1 billion.
• Lantern Pharma (NASDAQ:LTRN) shares moved upwards by 15.48% to $2.76. The company's market cap stands at $26.7 million.
• Alector (NASDAQ:ALEC) shares increased by 14.83% to $2.53. The company's market cap stands at $240.1 million.

Losers

• ProMIS Neurosciences (NASDAQ:PMN) stock fell 16.1% to $15.23 during Monday's pre-market session. The company's market cap stands at $39.0 million.
• bioAffinity Technologies (NASDAQ:BIAF) stock decreased by 12.74% to $1.85. The market value of their outstanding shares is at $9.5 million.
• Nasus Pharma (AMEX:NSRX) shares fell 8.21% to $4.59. The company's market cap stands at $58.5 million.
• Tivic Health Systems (NASDAQ:TIVC) shares declined by 7.45% to $0.87. The company's market cap stands at $1.6 million.
• Basel Medical Group (NASDAQ:BMGL) shares decreased by 7.19% to $0.57. The market value of their outstanding shares is at $11.6 million.
• Outset Medical (NASDAQ:OM) stock declined by 6.3% to $3.05. The company's market cap stands at $59.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.